Skin Cancer

Latest News



A new tumor staging system for cutaneous squamous cell carcinoma (CSCC) has recently been put forward that, according to one recent study, improves prognostic discrimination by more precisely defining the small subset of tumors with a high risk of metastatic and death.

Atypical fibroxanthoma (AFX) and undifferentiated pleomorphic sarcoma (UPS) share a similar histological picture. But unlike AFX, UPS can have an aggressive clinical course, underscoring the importance of initial accurate diagnosis of these tumors, and the implementation of appropriate therapy.

A new study suggests that topical 5-fluorouracil (5-FU) may increase the risk of morpheaform basal cell carcinoma (mBCC) in patients with previous skin cancers.

Some misconceptions have sprung up about sunscreen SPF values. Curtis Cole, Ph.D., sees a need to dispel some myths, and a need for for dermatologists to do a better job of educating their patients about sun protection.

New research suggests that the body’s internal clock and its circadian rhythms adjust the modulation of skin stem cells based on the time of day - and that disruption to this cycle can cause tissue aging and lead to predisposition to skin cancer.

The American Academy of Dermatology (AAD) Council on Science and Research’s Research Agenda work group has identified three keys areas - pruritus, cutaneous oncology and performance measurement and outcomes - to target in the future for continuing research in the dermatology specialty.

Melanoma is a hot topic on Twitter and thanks to hashtags, it’s easy to see what everyone is saying about the disease. Here are some recent posts about #melanoma that we found interesting this week.

Photographs of skin cancers caused patients to be more likely to conduct skin self-examinations, according to results of a recent study.

A new genetic test can identify patients with nonmetastatic melanoma who are at high risk of recurrence, according to validation data presented at the 2013 summer meeting of the American Academy of Dermatology.

Various approaches are being initiated to treat wild-type, BRAF mutated melanoma, according to the director of the Melanoma Program and co-leader of the Signal Transduction Program at Vanderbilt-Ingram Cancer Center in Nashville, Tenn.